[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341861-105":59,"doc-detail-341861-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeted-transcriptional-downregulation-of-myc-using-epigenomic-controllers-demonstrates-antitumor-activity-in-hepatocellular-carcinoma-models","Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models","","Master regulator c-MYC (MYC) dysregulation is central to hepatocellular carcinoma (HCC) and other cancers, yet has been difficult to drug directly. The article presents an epigenomic controller (EC), a programmable epigenomic mRNA therapy, designed to modify MYC-insulated genomic domain (IGD) subelements to drive methylation of MYC regulatory elements and durable downregulation of MYC mRNA transcription. Preclinical HCC models show significant antitumor activity as monotherapy or combined with tyrosine kinase or immune checkpoint inhibitors, supporting clinical translation of MYC-targeting ECs.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeted-transcriptional-downregulation-of-myc-using-epigenomic-controllers-demonstrates-antitumor-activity-in-hepatocellular-carcinoma-models/341861/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeted-transcriptional-downregulation-of-myc-using-epigenomic-controllers-demonstrates-antitumor-activity-in-hepatocellular-carcinoma-models/341861.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is MYC considered an elusive therapeutic target in hepatocellular carcinoma?","Question",{"text":113,"@type":114},"MYC inhibition has been difficult because the MYC protein lacks a structured binding pocket for small-molecule targeting, and MYC mRNA/protein turnover plus autoregulation would require sustained inhibition. The article frames epigenetic transcriptional control as an alternative strategy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the epigenomic controller downregulate MYC transcription?",{"text":118,"@type":114},"The epigenomic controller is designed to modify MYC IGD subelements, resulting in methylation of MYC regulatory elements and durable downregulation of MYC mRNA transcription. The approach is based on programmable epigenomic mRNA medicines and IGD biology.",{"name":120,"@type":111,"acceptedAnswer":121},"What antitumor outcomes were observed in HCC preclinical models?",{"text":122,"@type":114},"Significant antitumor activity was observed in preclinical HCC models treated with the MYC-targeted epigenomic controller. Activity was demonstrated both as monotherapy and in combination with tyrosine kinase or immune checkpoint inhibitors.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341861,1790309281,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Article [https://doi.org/10.1038/s41467-024-52202-y](https://doi.org/10.1038/s41467-024-52202-y)  \nTargeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models  \nReceived: 26 September 2023  \n\n| Accepted: 29 August 2024 |\n| --- |\n| |\n| Check for updates |\n\nWilliam Senapedis 1 , Kayleigh M. Gallagher1,2, Elmer Figueroa 1,3, Jeremiah D. Farelli 1, Robert Lyng1,4, J. Graeme Hodgson1, Charles W. O’Donnell1, Joseph V. Newman1, Madison Pacaro 1, Stephen K. Siecinski1, Justin Chen 1 & Thomas G. McCauley 1  \nDysregulation of master regulator c-MYC (MYC) plays a central role in hepatocellular carcinoma (HCC) and other cancers but remains an elusive target for therapeutic intervention. MYC expression is epigenetically modulated within naturally occurring DNA loop structures, Insulated Genomic Domains (IGDs). We present a therapeutic approach using an epigenomic controller (EC), a programmable epigenomic mRNA medicine, to precisely modify MYCIGD subelements, leading to methylation of MYC regulatory elements and durable downregulation of MYC mRNA transcription. Signiﬁcant antitumor activity is observed in preclinical models of HCC treated with the MYC-targeted EC, as monotherapy or in combination with tyrosine kinase or immune checkpoint inhibitors. These ﬁndings pave the way for clinical development of MYCtargeting epigenomic controllers in HCC patients and provide a framework for programmable epigenomic mRNA therapeutics for cancer and other diseases.  \nThe c-MYC (MYC) oncogene is a pleiotropic transcription factor (TF) that plays a central role in regulating the activity of tumor cells and the tumor microenvironment, driving initiation and maintenance of the tumor ecosystem. MYC inhibition in preclinical mouse models canelicit regression of established tumors in vivo1–3, mediated through a variety of distinct mechanisms including tumor cell proliferative arrest, senescence, and apoptosis, disruption of tumor-associated vascular- and stromal-cell activities, and prevention of immune evasion4–7. Interestingly, while systemic MYC inhibition in adult mice also elicits inhibitory effects on normal regenerating tissues such asthe intestinal and haematopoetic systems, these effects are generally well tolerated and reversible, even though antitumor activity is maintained8,9. The differential responses to MYC inhibition of tumor tissue versus normal regenerative tissues provide an attractive  \nopportunity to develop MYC inhibitors with potentially safe and effective therapeutic proﬁles in cancer patients.  \nDevelopment of targeted MYC inhibitors has proven elusive, in part, because the MYC protein lacks a structured binding pocket that can be effectively targeted by small molecule inhibitors4,10,11. Further, the short-lived expression of MYC mRNA and protein, combined with the multitude of oncogenic inputs that drive chronic MYC gene expression in tumor cells4,12, suggest that direct inhibition of the MYC transcript or protein would require maintaining effective drug exposures for sustained periods to offset the autoregulation of MYC expression in cancer cells.  \nTo address these challenges, we have leveraged a platform for gene control based on controlled epigenomic modulation of Insulated Genomic Domains (IGDs), which offers the potential to selectively and  \n1Omega Therapeutics, Cambridge, MA, USA. 2Present address: AstraZeneca, Waltham, MA, USA. 3Present address: Flagship Pioneering, Cambridge, MA, USA.  \n4Present address: SalioGen Therapeutics, Lexington, MA, USA. [e-mail:](e-mail: wsenapedis@omegatx.com)[ wsenapedis@omegatx.com](e-mail: wsenapedis@omegatx.com)  \ndurably downregulate MYC gene expression. IGDs are ubiquitous naturally occurring chromatin loop structures, conserved throughout mammalian genomes to compartmentalize and operationalize the vast amounts of information found in DNA13–15. IGDs enable targeted control of gene transcription via rapid, e","cbCaiiUmQQfseBLD","https://ap.wps.com/l/cbCaiiUmQQfseBLD","pdf",1721165,17,"English","# Abstract\n## Therapeutic rationale for MYC targeting\n## Epigenomic controller design and mechanism\n## Preclinical antitumor activity results\n## Clinical development outlook\n# Results\n## Design of OTX-2002-DS for durable MYC downregulation","[{\"question\":\"Why is MYC considered an elusive therapeutic target in hepatocellular carcinoma?\",\"answer\":\"MYC inhibition has been difficult because the MYC protein lacks a structured binding pocket for small-molecule targeting, and MYC mRNA/protein turnover plus autoregulation would require sustained inhibition. The article frames epigenetic transcriptional control as an alternative strategy.\"},{\"question\":\"How does the epigenomic controller downregulate MYC transcription?\",\"answer\":\"The epigenomic controller is designed to modify MYC IGD subelements, resulting in methylation of MYC regulatory elements and durable downregulation of MYC mRNA transcription. The approach is based on programmable epigenomic mRNA medicines and IGD biology.\"},{\"question\":\"What antitumor outcomes were observed in HCC preclinical models?\",\"answer\":\"Significant antitumor activity was observed in preclinical HCC models treated with the MYC-targeted epigenomic controller. Activity was demonstrated both as monotherapy and in combination with tyrosine kinase or immune checkpoint inhibitors.\"}]","Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models | PDF",1790044195,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59feb373d9b0108b5c37133aa28f66f9.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7554b8e660ad80503a1b92f593325612.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0813c4cd15def6590e90197218293ec.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad72a91c0858c4c7375f820ce7c6c89d.webp",980,1301]